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Abstract
An Examination of Eisenia fetida Coelomic Fluid for Antimycobacterial Activity

Christopher William Meiers
Master of Science In Biological Sciences
Minnesota State University, Mankato
November 2015

Antibiotic resistance is a growing problem with real world consequences to
human health and no known solution. The genus Mycobacterium contains
several bacteria that can cause serious illnesses including tuberculosis and
Johne’s disease. Some of these pathogens also have resistance to several
antibiotics. This project sought to find antimycobacterial activity related to the
phagocytic coelomocytes or soluble substances in the coelomic fluid of the
earthworm Eisenia fetida. The phagocytic activity was determined by observing
the adherence of phagocytes to Mycobacterium smegmatis (strain mc2155)
bacteria. The antimycobacterial ability of the coelomic fluid was assessed by
comparison of viable plate counts after treatment with coelomic fluid extracts.
The effect of disrupting the microbial flora of the earthworm on these
antimycobacterial affects was also investigated. No antimycobacterial activity

was observed in coelomic cells or extracts from earthworms with intact or
disrupted microbial flora. However, a trend of increasing coelomic cell
concentration after treatment of the worm with antibiotics was seen. There are
some aspects of the experiment that could be refined to examine the coelomic
fluid for antimycobacterial activity or antibacterial activity against other problem
bacteria more precisely. However, the more fruitful area of research would
appear to be examining the discrepancy in coelomic cell concentration between
antibiotic treated and untreated earthworms.
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1. Introduction
The growing threat of bacterial resistance to antibiotics is a significant
concern, as it makes treatment of diseases more challenging, more costly, or
even impossible (1). Researchers have searched for new antibacterial drugs in
increasingly diverse organisms and environments, including terrestrial
invertebrates (2). Invertebrates lack the specificity provided by the antibodybased immunity of vertebrates (3). Instead, they have a non-specific immune
system with humoral and cellular aspects (4,5). Investigation into the extracts of
numerous organisms including terrestrial invertebrates has led to the discovery of
several antimycobacterial compounds (6,7).
Earthworm coelomic fluid contains more than 40 proteins with cytolytic,
proteolytic, antimicrobial, hemolytic, hemagglutinating, tumorolytic, and mitogenic
activities (8-11). The coelomic fluid of the earthworm Eisenia fetida andrei has
antimicrobial activity against Aeromonas hydrophila and Bacillus megaterium,
both known earthworm pathogens (10,11).
Another aspect of earthworm innate immunity is the phagocytic activity of
coelomocytes. Coelomocytes have two general populations: amoebocytes and
eleocytes. The amoebocytes carry out phagocytosis and produce cytokines and
eleocytes collect contaminants and other stray matter in the coelomic fluid (12).
Amoebocytes are classified as either hyaline or granular based on their
appearance (12). The first step of phagocytosis, cell adhesion, begins with the
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association with surface receptors of the cell to the particle to be phagocytized
(13). If the particle or bacterium is small enough to ingest, phagocytosis
proceeds. However, if the particle is too large, such as an invading nematode,
amebocytes encapsulate the particle and the brown body that is formed moves
through the coelom toward the posterior body segments, which are detached with
the particle (11). After the immune cells of the worm phagocytize bacteria, the
bacteria clump together and then disperse. These bacteria are not found in the
nephridial walls, indicating the phagocytes are able to efficiently breakdown and
remove bacteria (14). The phagocytic activity of earthworm coelomocytes can be
assessed by microscopy. The amount of coelomic cells adhered to bacteria out
of the total coelomic cell population can be used as a measure of phagocytic
activity. It has been observed that the coelomic cells of Dendrobaena veneta
show an increased adherence of known earthworm pathogens (Bacillus
megaterium and Aeromonas hydrophila) over non-pathogenic species (15). This
phagocytic ability can be improved by humoral components and opsonins (12).
An example of this is seen in L. terrestris, where phagocytosis of yeast was
improved after opsonization with coelomic fluid (16). It is possible that this
activity may result from a compound produced by flora of E. fetida, which may be
able to enhance phagocytosis in its coelomocytes.
The association of bacteria and phagocytic cells is improved in the
presence of opsonins. In mammals, opsonic activity is associated with
complement and antibodies found in the serum (17). Beneficial bacteria may
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also contribute; one study of mouse monocyte-macrophage cells in vitro
demonstrated increased phagocytic activity in a dose-dependent manner using
cell-free lactic acid bacteria extract (18). This indicates that secretions from the
cells were promoting phagocytosis. Despite differences between mouse and
earthworm immune systems, it is possible that this occurs as a result of
secretions by earthworm bacterial flora as well. One of the bacteria in the
earthworm E. fetida is V. eiseniae. This bacterium present in the nephridia of the
worm still has no known function. It is possible that this bacterium or other flora
may have antimicrobial properties.
Earthworms interact with numerous soil organisms including species of
Mycobacterium. The genus Mycobacterium has had a significant impact on
human and animal health. The most high profile disease associated with this
genus is tuberculosis, caused by Mycobacterium tuberculosis. In 2013,
tuberculosis had an incidence rate of 9 million worldwide (19). Mycobacterium
leprae, the causative agent of leprosy, has had and still has an impact on the
human population. In 2012, there was a prevalence of 189,018 cases and an
incidence of 232,857 new cases was reported globally (20). Mycobacterium
avium subspecies paratuberculosis (MAP) is a veterinary pathogen; it causes
Johne’s disease, a wasting disease of cattle. This disease if left untreated,
causes malabsorption of nutrients in the cow intestine, which can eventually lead
to death in infected cattle (21).
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In humans, MAP has been suspected to be responsible for Crohn’s
disease, a disease with symptoms similar to those of in Johne’s disease (22).
The Mycobacterium avium complex is a collection of bacteria that cause
significant human disease. It is causes an opportunistic infection that produces a
vast array of symptoms including weight loss, diarrhea, fever, pneumonia, and
hepatitis. It is a disease common to immune compromised individuals, in
particular those in the HIV/AIDS population (23).
Antibiotic resistance in the genus Mycobacterium and in M. tuberculosis in
particular is a concern. M. tuberculosis is able to withstand many broad
spectrum antibiotics, which is problematic for treatment (24). Treatment of this
pathogen includes a multi-drug regimen that can take as long as 6 to 12 months
to complete and requires fairly strict patient compliance. The incomplete or
improper administration of this chemotherapy treatment has led to the
development of multi-drug resistant strains of the bacterium (25). In addition to
mutations that enable resistance to antimicrobial agents, mycobacteria are
naturally resistant to many common antibiotics. This is due to the intrinsic
impermeability of their cell wall that stems from the mycolic acid (26-29).
However, mycolic acids of the cell wall don’t explain the entirety of the resistance
seen in Mycobacterium (26). Synergistic effects have been investigated with
respect to resistance; research has determined that genes not involved in cell
wall assembly may work with those involved in cell wall assembly to enable
resistance to certain broad-spectrum antibiotics (30-32).
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With MAP infections in cattle, treatment with isoniazid alone or in
combination with rifampin for the duration of an animal’s life stops the
progression of Johne’s disease but doesn’t cure the animal. When treatment is
stopped, the bacterium again resumes growth and the animal progresses to a
disease state (33). Because treatment is not curative, it is rarely undertaken;
however, it may be considered for animals with exceptional genetic value (34).
MAP is a difficult pathogen to remove from the livestock environment as infected
cattle shed large numbers of the bacterium in their feces. MAP can persist in
black earth for 11 months and manure for a year (35,36). If cattle graze on grass
or eat soil contaminated by feces they have the potential to be infected.
Another cattle pathogen is Mycobacterium bovis, the causative agent of
bovine tuberculosis (36). In the United States, the prevalence of this bacterium is
much lower than that of MAP, as it has been eradicated in all but two states due
to a surveillance program that started in 1917 (37,38). This organism has also
been able to cause tuberculosis in humans, though this is a less common
occurrence compared to tuberculosis due to M. tuberculosis (39).
Due to the damaging impact associated with mycobacterial diseases and
the development of antibiotic resistant strains, new antibiotics and treatment
regimens should be developed. One can look to organisms that have to deal with
mycobacteria in their everyday environment. Since earthworms are residents of
soil and manure, where MAP is known to persist, specific attention has been paid
to earthworms (36). When Lumbricus terrestris earthworms were placed in a
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highly MAP-contaminated environment and subsequently tested for the
presence of the bacterium, few of them had culturable bacteria (40). The
antimycobacterial activity of the earthworm Dendrobaena veneta stemmed from
compounds produced by a bacterium that is a close relative of Raoultella
ornithinolytica, (99% sequence similarity). R. ornitholytica is a suspected
symbiont present in the midgut of the earthworm. The authors found the
bacterium in the intestinal wall of D. veneta worms from multiple different soil
sources indicating the organism is not merely an acquired soil organism. The
metabolites made by the bacterium were postulated to interfere with cell wall
synthesis as evidenced by the rounded or filamentous forms of the mycobacterial
cells observed via scanning and transmission electron microscopy (7).
Investigations of soil bacteria for antibiotic compounds have yielded results in the
past. The soil organism Streptomyces griseus produces a compound used to
derive the anti-tuberculosis drug streptomycin (41). Thus, the earthworm and its
bacterial flora may provide a source of antimycobacterial substances.
Commensal and symbiotic bacterial association with the earthworm has
been investigated in several instances, though much of the mechanism of
establishment has yet to be elucidated. In one study, it was found that there was
an increase in unrelated bacterial diversity when E. fetida was exposed to E. coli
0157:H7. The new bacteria then decreased following the elimination of E. coli on
day 2 (42). It was proposed that one of the established gut bacteria, a Bacillus
species, had an antagonistic relationship with the E. coli, likely secreting a
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specific antimicrobial substance. In other words, bacteria antagonistic to E. coli
including the Bacillus species exist as gut bacteria normally, but at a lower level.
When a pathogenic challenge is detected, these bacteria increase to a detectable
level and inhibit the invading bacteria (42).
In the earthworm E. fetida there is a symbiont, Verminephrobacter
eiseniae that colonizes the nephridia of the worm. If this bacterium has a role in
the earthworm it is unknown, but it is retained and vertically transmitted to their
offspring cocoons (43,44). Following hatching of the juvenile worm from the
cocoon, the worm is unable to acquire the symbiont or other bacteria (44). Thus,
when one is assessing the presence or absence of V. eiseniae in an adult worm,
one can either look to the nephridia of the worm or look to the cocoons produced
by the worm.
The purpose of this study was to determine whether or not V. eiseniae,
produces antimycobacterial compounds or stimulates phagocytosis.
Unfortunately many of the Mycobacterium species discussed have slow
generation times. It can take up to four months before visible MAP colonies can
be seen on solid media; others take even longer (40). Therefore, in order to
study the effects of substances on any mycobacteria, a common strain of M.
smegmatis, mc2155, is used for the study of M. tuberculosis and MAP due to its
genetic similarity and faster generation time (45).
The purposes of this study were 1) to determine whether or not there are
antimycobacterial compounds present in the coelomic fluid of Eisenia fetida
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earthworms and whether there is a vertically transmitted bacterium, which
affects that ability and 2) to determine whether the phagocytic cells present in the
coelomic fluid interact with mycobacteria at a higher level when there is verticallytransmitted bacterium present in the worm.
The hypothesis for this study was: The coelomic cells and fluid of the
earthworm E. fetida have antimycobacterial properties, which may or may not be
influenced by the presence of V. eiseniae. If true, the treatment of M. smegmatis
with E. fetida coelomic fluid should show a decrease in bacterial concentration.
Also, phagocytic activity should be apparent based on adherence of phagocytes
to M. smegmatis. If symbiotic bacteria have an affect on phagocytic coelomic
cells, the amount of cells interacting with M. smegmatis should be positively or
negatively with the loss of the symbiont.
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2. Literature Review
Overview
The overall goal of this project was to assess the earthworm Eisenia fetida
for antimycobacterial activity. In order to understand why this project was
undertaken, information on the specifics surrounding the earthworm, the genus
Mycobacterium, and antibiotic discovery need to be elucidated. For E. fetida,
anatomy, immune function, and symbiotic bacteria of the earthworm will be
discussed. For the mycobacteria, common pathogenic species and antibiotic
resistance mechanisms will be analyzed. Natural sources of antibiotics will also
be examined. These areas will provide a basis for understanding how new
antimycobacterial compounds might be discovered in E. fetida.

Mycobacterium and Antibiotic Resistance
The genus Mycobacterium is largely composed of saprophytic soil
microorganisms that are often associated with sphagnum moss, surface and
drinking water, and soil with organic materials (36). This genus, composed of
>50 species, is related to Streptomyces and Actinomyces. There are several
successful pathogens in Mycobacterium including Mycobacterium tuberculosis,
Mycobacterium leprae, and Mycobacterium avium subspecies paratuberculosis
the causative agents of tuberculosis, leprosy, and Johne’s disease, respectively
(46). The saprophytic organisms in this genus are slower growing compared to
many other bacteria. However, most pathogenic mycobacteria take weeks to
months to form colonies, and one has yet to be grown in culture, therefore since
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the saprophytes tend to only take 7 days to form colonies on a plate they are
desirable for their use in research (47,48). Mycobacterium tuberculosis can take
2 to 4 weeks and Mycobacterium avium subspecies paratuberculosis colony
formation takes 3 months or more (49,50).
These organisms are nonmotile, nonsporulating, weakly Gram-positive,
acid-fast bacilli, which appear as straight or slightly curved rods. They are 1 to 4
µm in length and 0.3 to 0.6 µm wide (51). These bacteria have mycolic acids that
are critical to the cell wall (52). The waxy phenotype of the cell wall conferred by
these acids results in: acid-fast staining, hypdrophobicity, and resistance to
drying, acidity/alkalinity, and many antibiotics. Mycolic acids have
immunostimulatory properties for the host immune system (53). These also allow
for rapid diagnosis of mycobacteria by way of the acid-fast stain or Ziehl-Neelsen
that identifies bacteria possessing mycolic acids (acid-fast) versus those that
don’t (non-acid-fast) (based off a translation in Kazda et. al.) (36,54,55). Using
this technique one can easily detect acid-fast mycobacteria in sputum samples.
Much of the antibiotic resistance of Mycobacterium is an intrinsic
resistance based primarily on the impermeability of the cell wall (26,27). No
horizontal transfer via plasmids or transposons has been observed: thus, these
resistances most likely arise by chromosomal mutations that occur as a result of
selective pressure from antibiotic use (56). However, it has been found that cell
wall composition doesn’t entirely explain the observed antibiotic resistance (26).
Thus, synergistic effects related to genes not involved in cell wall assembly that
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enable resistance to some broad-spectrum antibiotics have been investigated
(30-32). These include modification of drug targets such as ribosomal RNA,
chemical modification of the antibiotic such as the acetylation of amine groups in
aminoglycosides, enzymatic degradation of drugs such as β-lactamase activity,
molecular mimicry of drug targets such as the production of MfpA as a decoy
sequence for fluoroquinolones, and the use of efflux pumps to remove antibiotics
from the bacterium (57-63).

Mycobacterium tuberculosis
The most well known member of this genus, Mycobacterium tuberculosis,
causes the lung disease tuberculosis (TB). The symptoms of pulmonary TB
include chronic cough, sputum production, appetite loss, weight loss, fever, night
sweats, and hemoptysis (64). Other less common bacteria in this genus
including Mycobacterium africanum, Mycobacterium canetti, Mycobaterium bovis,
Mycobacterium caprae, Mycobacterium myroti, and Mycobacterium pinnipedii
can also cause tuberculosis (36). In 2013 there was an incidence of 9 million
tuberculosis cases worldwide, that same year 1.5 million people died from the
disease (19).
In more than 90% of cases of this disease, the bacterium is contained as
an asymptomatic latent infection (65). Transmission of this bacterium is typically
through contaminated aerosol from an infected person; however, it can also be
shed in feces, urine, and other excretions and secretions (36). Without
treatment, approximately 5-10% of TB infected individuals will develop active TB
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(66). A latent infection is associated with a lower risk of reinfection after
another exposure (67). Conversely, if progression to active infection occurs and
is treated, there is an increased risk of a second episode of TB on reexposure
(68,69). Diagnosis of the latent form of this disease is typically done by a
tuberculin skin test or an interferon-gamma release assay (65). The tuberculin
skin test or Mantoux tuberculin test is performed by injecting 0.1mL of tuberculin
purified protein to the forearm; a further swelling of the injection site indicates an
inflammatory action of T helper lymphocytes. This means the individual is likely
infected with the bacterium, however a false positive can result if they have been
infected with mycobacteria including M. tuberculosis previously; thus, a
confirmation may be undertaken to confirm the diagnosis (70). Active TB
diagnosis is typically performed via sputum microscopy and culture in a liquid
medium with associated drug susceptibility testing (65). However, a new
molecular test, Xpert MTB/RIF, detects M. tuberculosis complex within 2 hours
using real time PCR to amplify a specific mutated sequence of the M.
tuberculosis rpoB gene that indicates rifampin resistance. This method is a more
sensitive method than smear microscopy (71-73).
One of the key aspects of M. tuberculosis pathogenicity is the invasion of
macrophages of immunocompetent individuals (74). This bacterium is able to
use several strategies to evade destruction by macrophages. These include
disruption of: phagosome-lysosome fusion, recruitment of hydrolytic lysosomal
enzymes, reactive oxygen and nitrogen species production, antigen presentation,
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and MHC class II expression and trafficking, autophagy, and apoptosis (74).
Entry into the macrophages requires recognition of the bacterium by several
opsonic and non-opsonic receptors (75). The non-opsonic method uses pattern
recognition receptors (PRRs), which recognize pathogen-associated molecular
patterns (PAMPs) (76). In the case of opsonic uptake of M. tuberculosis, there is
recognition of coated bacteria with complement factors, antibodies, and/or
surfactants (77). However, most agree that ingestion of the bacterium occurs by
non-opsonic means in the early stages of infection (77-80). Non-opsonic entry
into the macrophage has been found to be associated with higher intracellular
survival than opsonic entry; this suggests specific receptors need to be used to
disrupt phagosome-lysosome fusion (78).
Immune CD4+ T lymphocytes protect against TB, however some research
indicates the participation of CD8+ T lymphocytes (81-84). The risk of developing
active TB increases soon after infection with HIV, due to a lower population of
functioning T lymphocytes (85). In 2013 1.1 million were HIV positive of a total
incidence of 9 million (19). Once CD4 cell counts reach less than 200 per mm3,
the presentation of TB becomes atypical. Subtle infiltrates, pleural effusions,
hilar lymphadenopathy, and other forms of extrapulmonary TB appear in up to
50% of patients (65). When CD4 counts reach less than 75 per mm3, pulmonary
evidence may be lacking, and disseminated TB manifests as a nonspecific,
chronic febrile illness with bacterial distribution to other organs. In these
instances bacteremia is more frequent. This results in high early mortality. The
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HIV positive status is also associated with multiple M. tuberculosis strain
involvement (86).
Treatment of TB is not simple. For latent TB, the regimen is isoniazid
alone for 9 months in a healthy individual or longer for HIV-infected individuals
(87,88). For active TB, a four-drug regimen of isoniazid, rifampin, pyrazinamide,
and ethambutol is effective in 90% of cases in which no drug resistance is
detected (89). The 6-month treatment program requires an initial 2 months of
treatment with all four antimycobacterial drugs followed by 4 months of isoniazid
and rifampin. If risk factors for relapse (including cavitation, extensive disease,
immunosuppression, or a positive sputum culture at 8 weeks) are present, the
therapy can be extended up to 9 months (65). Barriers to the efficacy of this
regimen include: inconsistent drug quality, treatment interruptions due to side
effects, toxic effects, pharmacokinetic interactions (such as with antiretrovirals for
HIV), and compliance issues due to the length of treatment (65,90). In an
attempt to reduce the therapy to a more manageable 4 months, some trials have
added or substituted fluoroquinolones or added higher doses of rifamycins (65).
A global report on TB by the WHO in 2014 estimated that the proportion of
multi-drug resistant TB (MDR-TB) was between 14 and 28%, of these, 9% were
extensively drug resistant TB (XDR-TB) (19). Eighty-four countries that have
reported extensively resistant strains that have resistance to fluoroquinolones
and the injectable drugs: kanamycin, amikacin, and capreomycin (89,91,92).
Improper use of anti-TB drugs including using monotherapy and adding a single
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drug alongside currently failing drugs has favored the cultivation of these
resistant mutants via selective pressure (65). Unfortunately, it is estimated that
only 10% of cases of MDR-TB are currently diagnosed worldwide, and only half
of these receive appropriate treatment (89,91,92).
MDR-TB is typically treated using either standardized treatment or
individualized treatment once the empirically determined resistance pattern of the
bacterium becomes known (65). These regimens typically require combination
drugs from five groups of first-line and second-line drugs, which need to be used
for 20 months or 30 months for those who have had MDR-TB previously (65,93).
Another treatment, the Bangladesh regimen, is a 3-stage regimen that involves a
shorter treatment time of 21 months with fewer adverse effects and more positive
outcomes including some showing no identifiable bacteria at 3 months. This
treatment is a standardized treatment based on the resistance pattern observed
in a sampling of the population (94). This allows for less extensive
hospitalization and less time waiting on individual culture tests. XDR-TB is a
greater challenge to diagnose and treat; it has been associated with an extremely
high death rate among HIV-infected individuals (95,96).
Some new drugs have shown some activity against MDR and XDR-TB
and are being investigated further; several of these drugs have new mechanisms
of action against M. tuberculosis. These include new fluoroquinolones that inhibit
topoisomerase IV and DNA gyrase, new nitroimidazoles that inhibit mycolic acid
synthesis in replicating TB and generate highly reactive nitrogen radicals in non-
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replicating TB, bedaquiline that inhibits ATP synthase, new oxazolidinones that
inhibit translation by blocking binding at the A site of peptidyl transferase center
of the mycobacterial ribosome, and SQ109 that inhibits the MmpL3 transporter,
necessary for the integration of trehalose mycolate,into the cell wall (65). One
three-drug treatment including moxifloxacin, pyrazinamide, and PA-824 showed
14-day bactericidal effect similar to that of the standard four-drug therapy (97).
The Mycobacterium bovis Calmette-Guérin (BCG) attenuated vaccine is
commonly used in areas where TB is endemic (65). The prevention efficacy of
this vaccine is approximately 50% (98). The vaccine is not appropriate for use in
immunosuppressed individuals as it has the potential to cause a fatal
disseminated infection (65). The restrictions of this vaccine have led others to
investigate other options; over 30 vaccines are in development (99). Another TB
vaccine uses Mycobacterium microti, which has the same level of efficacy (100).
Unfortunately, the use of these vaccines undermines the efficacy of tuberculin
skin testing (66).

Mycobacterium leprae
Leprosy, caused by Mycobacterium leprae, was first described in 460 BC
by Hippocrates, though archaeological evidence from Egypt suggests indicates it
has been around since 4000 BC (48). Leprosy, also called Hansen’s disease,
has an array of symptoms including skin lesions; growths on the skin; thick, stiff,
or dry skin; severe pain; numbness on affected areas of skin, muscle weakness
or paralysis, eye problems including eventual blindness, enlarged nerves, and
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ulcers on the soles of feet (101). Like many others in the genus
Mycobacterium, M. leprae has a long incubation period and it can take from 5 to
20 years to appear (20). This disease is not just one of historical record; in 2012
there was a prevalence of 189,018 cases, with 232,857 new cases globally (20).
Even though this disease has been around since early-recorded history,
the causative agent, M. leprae, wasn’t determined to be the cause until 1875
(102). This proved to be a difficult pathogen to grow outside of the infected host;
it wasn’t done until 1960 when it was successfully grown in mouse footpads. It
has yet to be cultured in vitro (103). A more recent discovery is that another
species, Mycobacterium lepromatosis, also causes leprosy (104). In the 1960s,
a multidrug regimen including dapsone, rifampicin, and clofazimine was
developed after resistance to dapsone alone occurred (20). Fortunately, at this
point no resistance to this multidrug treatment has been reported (20).
It is generally understood that transmission of this disease is airborne and
by direct skin contact by an infected individual (36). This bacterium has also
been isolated from feral nine-banded armadillos, which indicates that infected
individuals aren’t the only source of this pathogen. It has also been postulated
that polluted drinking water may be a source (36). Some support for this was
seen in Indonesia, where PCR testing was performed for M. leprae DNA. These
tests indicated a higher prevalence of leprosy amongst individuals that used
contaminated water for bathing and washing clothes or dishes (105).
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Mycobacterium bovis
Mycobacterium bovis is a cattle pathogen, the causative agent of bovine
tuberculosis (36). This is currently of lower concern than other cattle pathogens
as it has been eradicated in all but two states due to an eradication program that
started in 1917 (37,38). This organism has also caused tuberculosis in humans,
but is a much less common occurrence compared to that caused by M.
tuberculosis (39). However, disseminated infections in individuals with
immunodeficiencies can result from vaccination with BCG. As such, it has been
seen that areas with large populations of AIDS patients are showing these
complications to the vaccine (106). Unfortunately, treatment of adverse reactions
and disseminated BCG infection is still controversial, as the multiple strains with
different resistance patterns are used, and there is no standardized treatment at
present (107-109). Since multiple strains of BCG are used in the creation of this
vaccine, the treatment of each strain needs to be done according to the strain’s
susceptibility pattern to different antituberculosis drugs (110).

Mycobacterium avium subspecies paratuberculosis
There are several diseases associated with Mycobacterium avium
subspecies paratuberculosis (MAP); some are veterinary diseases, while others
are found in human populations. A German veterinarian Heinrich Johne first
described MAP as the causative agent of Johne’s disease in 1895 (111). Several
other Mycobacterium avium subspecies are also associated with disease. These
include M.a. hominisuis, which causes avian mycobacteriosis in humans, pigs,
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cattle, and other animals, M.a. silvaticum, which causes disease in wild and
domestic birds, and M.a. avium, the causative agent of avian tuberculosis in
birds, domestic pigs, cattle, and other mammals (36). The chronic inflammation
of Johne’s disease results in malabsorption of nutrients in the intestine, which
can lead to death in the cow (8).
Johne’s disease is a significant problem in agriculture with an estimated
cost between $200 and $250 million based on lost dairy production (112).
Another estimate puts the costs at closer to $1.5 billion (113). These costs are a
result of direct and indirect losses. Direct losses include mortality of infected
animals and the resulting decreased slaughter value, decreased milk production
in quantity and quality resulting from mastitis, decreased pregnancy rate and
postpartum complications, poor food conversion in clinically or sub clinically
infected animals, decreased productive age in infected animals, and increased
predisposition to other chronic diseases. Indirect losses include unrealized future
income by breeding animals being prematurely culled, increased expenses from
idle production, increased expenses for herd replacement, expenses for
diagnostic testing for MAP and associated veterinary care for ill animals,
expenses for a control program, lost genetic value of desirable animal traits,
expenses associated with trade restrictions, and lost reputation of a farm with
infected animals (114).
Due to the high losses associated with this disease, a means of
successful treating of cattle would be desired. Treatment with isoniazid alone or
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in combination with rifampin for the duration of an animal’s life can stop the
progression of MAP but doesn’t cure the animal. When treatment is stopped, the
bacterium again progresses to the disease state (33). Because treatment is not
curative, it is rarely undertaken, although it may be considered for animals with
exceptional genetic value for the breeding life of the animal (34). MAP is also a
difficult pathogen to remove from the environment of the cattle. Infected cattle
can shed the bacterium in their feces; the bacterium can persist in black earth for
11 months and manure for a year (35,36,115). As such, MAP can be found in
soil, manure, and surface water as a result of cattle fecal contamination (116118). Some MAP bacteria have been found in free-living amoebae in fields,
which indicates they may persist due to their ability to infect the amoebae (119).
Due to the ubiquity of the bacterium in the farm environment, it is easy for
uninfected cattle to acquire the pathogen simply from grazing and drinking.
Without a proper curative treatment, the cost of an MAP infection in a herd of
cattle can be devastating to the financial success of the farm.
Organisms belonging to the Mycobacterium avium complex (MAC) cause
opportunistic infections with a vast array of symptoms including weight loss,
diarrhea, fever, pneumonia, and hepatitis. The MAC cause a disease common to
immune compromised individuals, particularly those in the HIV/AIDS population
(23). It can cause chronic lung disease in immunocompetent individuals and
disseminated disease in those with AIDS (120). This disease has a similar
resistance pattern to other mycobacteria. A multidrug regimen including
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macrolides has been demonstrated to be the most effective treatment
(121,122). Unfortunately, the newer regimen has been found to have increased
adverse effects including drug toxicities exacerbated by interactions with other
drugs (123). Also, despite an improved treatment success, it is still not deemed a
satisfactory regimen (120). MAC has also been found to be a rising problem in
those with functioning immune systems (124).
A human disease with a suspected mycobacterial origin is Crohn’s
disease (CD), a chronic inflammation of the bowel in humans. It can affect those
with a normal immune system; it is also suspected that MAP causes this disease
(22). Some of the support for MAP as an etiologic agent of CD includes:
1. Examination of diseased intestinal tissue from Crohn’s patients and
Johne’s diseased intestinal tissue show similarities. This led researchers
to conclude they may be caused by the same bacterium (125). Both of
these diseases share symptoms such as weight loss and chronic diarrhea,
they also both produce tissue with granulomas and inflammatory action in
the small bowel and the colon (126). Unfortunately, detection of MAP in
human patients with Crohn’s was unsuccessful in these studies.
2. Tests for the MAP-specific protein tyrosine phosphatase A have shown a
significant increase in CD patients in comparison to the control group
(127).
3. Several studies have detected MAP at a higher frequency in the blood and
tissue of CD patients than in those of unaffected individuals (128-131).
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4. MAP isolated from a CD patient was inoculated into a young goat,
which subsequently acquired Johne’s disease, this indicates that the
transference of the inflammatory symptoms after infection (132).
The etiology of the disease remains unknown but it is typically understood
to involve genetic, environmental, and immune factors coupled with increased
inflammatory action (133).
Proponents of a bacteria-associated disease have postulated that
pathogenesis occurs when a genetically susceptible host ingests the bacterium.
The organism enters the intestinal wall via disrupted epithelium. MAP then
stimulates an immune response perpetuated by immune reactivity to the
organism. The bacterium is then ingested by intestinal macrophages, the
bacteria have been observed in a different form devoid of a cell wall (spheroplast)
(134). Once inside the bacterium can exist in a latent form for years, with the
potential to produce several inflammatory mediators that have been observed in
CD affected individuals (135). These mediators also stimulate naïve T cells to
differentiate into T-helper 1 cells, which stimulate macrophages to secrete further
inflammatory mediators. These cytokines activate natural killer cells, which
produce the tissue damage common to CD (136). Another observation that
supports an association between MAP and CD is that peripheral blood
mononuclear cells (PBMCs) isolated from CD patients could be induced to
produce T cells and secrete inflammatory cytokines such as TNF-α and IL-10
when incubated with MAP (137).
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The NOD2/CARD15 gene is one associated with the development of
CD (135,138). Individuals with mutations in this gene have a malfunctioning
innate response to bacterial infection; thus, it may be associated with a poor
clearing of intracellular MAP. This is a proposed connection for CD and MAP
causation (139). Some supporting evidence of this is shown in PBMCs from CD
patients who have NOD2 mutations, thus they lack proper recognition of MAP
(140). Some support for this idea is given in the identification of CARD15 single
nucleotide polymorphisms; this genetic type in cattle has shown a higher
susceptibility to MAP infection (141).
As was stated previously, infected cattle can shed MAP containing feces,
which can contaminate soil and surface water (116-118). Contaminated manure
from cattle can also contaminate crops and drinking water, which can contribute
to human exposure (142,143). One study has shown that MAP bacteria are able
to form biofilms in water systems for several weeks even under high flow
conditions (144). In addition to these forms of contamination, dairy products
including pasteurized milk and milk powder for infant formula can also harbor
MAP, which may expose individuals to MAP bacteria (145-147). Though there
hasn’t been conclusive evidence that the consumption of MAP in these has lead
to the development of CD (148). There has been evidence of a systemic
infection with the detection of MAP in breast milk of CD patients whereas
lactating control individuals didn’t have the bacterium (149). Despite the
presence of MAP in breast milk, no evidence of vertical transmission to offspring
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has been observed (150). It has been postulated that MAP can exist in
systemic and local forms (130). It has also been postulated that soil may serve
as a source of mycobacterial infections including M. avium infection (151-154).
As it stands there has been difficulty in detecting MAP in the blood and
tissues of immunocompetent CD patients via direct observation (155). However,
there has been some success in culturing the bacterium from the intestines of
several Crohn’s disease patients (132). Some research supports the idea of a
morphologic change to a smaller spore morphotype that survives heat and other
stressors, which may allow for survival in the host and the environment (156).
This may also explain the difficulties in culturing of the organism, this challenge in
culturing continues to contribute to the debate as to whether MAP is a pathogen
causing damage to the host or is just a transient bacterium associated with the
environment (126). Some research indicates bacterium has a modified cell wall
when present in humans, thus it no longer has an acid-fast character (157). It is
challenging to isolate MAP DNA from soil, as humic acids and other organic
material often affect its extraction. Instead either denaturing gradient gel
electrophoresis or T-RFLP alongside cloning and sequencing is often performed
(158-160). Due to challenges culturing the bacterium, PCR for IS900, an
insertion sequence specific to MAP is commonly used for detection of the
bacterium (116,117,161,162).
The evidence linking the relationship between MAP and CD is conflicting,
for example, as some phenotypes of CD are not present in Johne’s including
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fibrosis, fistulae, fissures, and pseudopolyps (163). It has also been shown
that farmers consistently exposed to MAP-infected cattle have shown no higher
prevalence of CD (164). Another somewhat confusing observation is that MAP
presence is decreased in immunosuppressed individuals. One explanation is
that MAP doesn’t cause CD, but is able to thrive in the immune dysfunction and
inflammatory environment caused by CD (126). Based on current evidence it is
no defined etiology of CD by MAP is possible.

Mycobacterium smegmatis as a Model Organism
Mycobacterium smegmatis is a common environmental bacterium found in
soil, dust, water, animal tissue, and human genital secretions (165). It was first
isolated from syphilitic chancres in 1884 by Sigmund Lustgarten (166). It was
later determined that M. smegmatis is not associated with disease when it was
found in normal human genital secretions (smegma) (translation from article by
He and De Buck) (167,168). This bacterium has only rarely has acted as a
pathogen; these are typically disseminated infections in soft tissues, usually
associated with immunosuppression (165,169-171). As with other mycobacteria,
M. smegmatis is resistant to some antibiotics including isoniazid and rifampin,
however it is susceptible to ethambutol, imipenem, doxycycline,
sulfamethoxazole, amikacin, and ciprofloxacin (171). It also has cell wall similar
to its pathogenic relatives such as M. tuberculosis, MAP, M. leprae (168). The
similarities don’t end at its cell wall; the genome of M. smegmatis has homology
to those relatives, which makes it ideal for studying those pathogens (45).
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Due to these similarities, this organism is commonly used to study
pathogenic mycobacteria (172). M. smegmatis is a faster-growing bacterium (3
to 4 hr. doubling time) with a fully sequenced genome, making it a useful model
organism The mc2155 strain is commonly used (168,173).

Natural Sources of Antimicrobial Compounds
Antimicrobial resistance in bacterial populations is a significant problem.
The treatment of disease becomes more challenging, more costly, or impossible
in these instances (1). Many currently available antibiotics have been derived
from natural sources including terrestrial plants, microorganisms, vertebrates,
and marine invertebrates (174). In one survey, approximately 66% of 148 were
either natural products or derived from a natural product scaffold (175).
One of the most famous antibiotics is penicillin, a compound that was
discovered by Alexander Fleming in 1928. He observed that the fungus
Penicillium notatum secreted a substance that inhibited the growth of
Staphylococcus aureus (176). Therapeutic use of the drug wasn’t fully realized
until the first successful treatment of a patient with streptococcal septicemia in
1942 (177). Penicillin (which acts on enzymes referred to as penicillin-binding
proteins (PBPs)) contains a beta-lactam ring that interrupts the formation of
peptidoglycan in bacterial cell walls (178).
An antibiotic more germane to the subject at hand is streptomycin, the first
drug used to remedy tuberculosis (179). Selman Waksman, a soil microbiologist,
isolated this antibiotic. It was found to be the most potent antimycobacterial
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substance of 10 other candidates (180,181). This compound was isolated
from the bacterium Streptomyces griseus by one of Waksman's collaborators
Albert Schatz (182). This drug acts as a protein synthesis inhibitor and works by
binding the 16S rRNA of the 30S subunit of the bacterial ribosome (183).
However, bacteria gain resistance to this antibiotic via mutations of the ribosomal
proteins (184).
As mentioned above, some terrestrial invertebrates have been examined
for antimicrobial activity. Limited specific attention has been focused on these
invertebrates in regards to antimycobacterial activity. Most studies are indirect
and linked to the fact that MAP is able to persist in soil and feces, which
earthworms can inhabit (36). A few studies have examined the interaction
between mycobacteria and earthworms. In one study, Lumbricus terrestris
earthworms were placed in a highly MAP contaminated environment; these
worms were then tested for the presence of the bacterium and a low proportion of
them had culturable bacteria (40). However, this study did not elucidate the
mechanism the observed failure of MAP to colonize the worm. Another study
found that antimycobacterial activity of the midgut of the earthworm Dendrobaena
veneta stemmed from a close relative (99% sequence similarity) of Raoultella
ornitholytica. It has been postulated that this suspected symbiont produced
metabolites that disrupted cell wall synthesis. This was evidenced in rounded or
filamentous forms of mycobacterial cells when observed using scanning and
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transmission electron microscopy. R. ornithinolytica is consistently found in
the intestinal wall of worms from several different soil sources (7).

Eisenia fetida and its Symbiont Verminephrobacter eiseniae
Several pathogens are associated with soil: opportunistic or emerging
pathogens present in the soil microbiota such as Aspergillus fumigatus spores
that may be inhaled causing disease and soil-based diseases caused by
pathogens that exist in the soil naturally or enteric pathogens that enter via
human or animal excrement such as Clostridium tetani, Bacillus anthracis, and
Clostridium perfringens (185). Current human waste disposal practices may
allow the accumulation of large concentrations of enteric pathogens into soil that
can contribute to some of these exposures (186). Several outbreaks have
stemmed from water exposed to contaminated soil (187-190). Other common
outbreaks of disease are related to fecal-contaminated soil in produce (190-192).
MAP has been detected in soil as well as M. leprae indicating soil may be a
reservoir for M. leprae (154,193,194). Contamination of this soil also occurs by
fecal contamination by animals and survival for up to a year or longer due to
association with amoebae or other protozoa (119). Soil bacteria also interact
with various invertebrates including earthworms (195-199). In the case of
earthworms, most of these bacteria go through the digestive tract and are
excreted (200).
The earthworm Eisenia fetida, from the family Lumbricidae, typically
inhabits areas rich in organic material such as manure, horticultural land, and
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forests with large amounts of leaf liter (201). These annelids are commonly
used in vermicomposting and ecotoxicological studies. They are also used for
comparative biochemistry, physiology, and immunology studies (202). The worm
is epigeic, meaning it exists in the top layer of its habitat. The top layer of soil is
rich in decaying organic matter; this layer also contains a high variability in
microbiota (202). As earthworms digest organic matter, their digestive system
disintegrates, grinds, and degrades this material. These activities can be
affected by the activity and concentration of beneficial and pathogenic microbes;
these can include beneficial and pathogenic fungi, actinomycetes, and bacteria
(203). Microorganisms in the digestive system are the most important to
earthworms with regard to the degradation of organic matter (204). In addition,
organisms in earthworm intestines including Bacillus, Pseudomonas, Klebsiella,
Azotobacter, Serratia, Aeromonas, and Enterobacter species are plant growth
promoters, free-living nitrogen fixers, and phosphate solubilizers that are
deposited by earthworms in their passage through the soil (204-207). The results
of one study on intestinal microbial diversity revealed that the gut of E. fetida
housed 21 taxa of bacteria (208).
Symbiotic bacteria have many roles in the lives of their hosts; these
include development, nutrition, reproduction, speciation, antimicrobial defense,
and immunity (209-219). Obligate symbionts show very specific interactions with
the host’s cells in numerous invertebrates. They are transmitted vertically from
the mother to eggs or embryos. The bacteria then go on to colonize the progeny
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during their development (209). Mutualistic bacteria have been able to
develop such that they don’t harm their host, but confer beneficial attributes to
the host; this symbiosis is sometimes necessary for bacterial survival (220). In
one well-studied bacterial symbiosis, Vibrio fischeri allows the squid Euprymna
scolopes to mask its position from predators by using V. fischeri bioluminescence
to hide its shadow (221). Another example of a highly beneficial relationship is
that of reef-building corals and photosynthetic algae. In this instance the algae
perform photosynthesis, producing glucose, glycerol, and amino acids. In some
instances the growth and formation of reefs is only possible with algae present in
the coral (222).
Numerous bacterial symbionts of various earthworm species have been
identified. Often these bacteria are identified via isolation on selective media and
genetic identification (223-228). Identification is often performed indirectly by
sequencing the contents of the worm, as some are not cultivatable at present
(228). Suspected symbiotic microbes present in the earthworm gut can be
identified by their genome; however, they need to be distinguished from soil
organisms that transit through the digestive tract (208). These microbes have
been found to be highly beneficial to the earthworm health. In one report, young
hatched from sterilized E. fetida cocoons were unable to reach sexual maturity
when raised in sterilized soil unless protozoa were added to their food (229).
In E. fetida, the first described obligate symbiont doesn’t lie in the intestine
but in the nephridia of the worm. The nephridia are paired organs with three
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loops; these are present in every segment of the earthworm, there are 200 in
total. These take in fluid that comes from the coelom, a cavity surrounding the
intestine of the worm (230). The ciliated mouth of the nephridia, called the
nephrostome, takes in this coelomic fluid from the coelom and blood from the
vessels. After passage through the different loops of the nephridium, nitrogenous
waste is excreted through the nephridiopore. The nephridia also have an
osmoregulatory function (230). The symbiont present in the ampulla (the second
loop) of the nephridia was first identified in 1926 by microscopic observation
(translation in Davidson et. al.) (44,231). These bacteria were first genetically
identified as belonging to the genus Acidovorax (232). A closer examination via
16S rRNa analysis of this bacterium identified it as being in a newly identified
genus and species Verminephrobacter eiseniae (233). The function of this
bacterium in the worm remains unknown; one proposed purpose has been
proteolysis to allow better absorption and amino acids (translation from Lund et.
al.) (234,235). This may increase nitrogen excretion by earthworms, which
releases nitrogen into the soil (232).
While the function of the bacterium has been thus far ambiguous, the
colonization of the symbiont has been well investigated. These bacteria are
transferred from adult worms to their offspring in egg capsules during mating. It
was also demonstrated that it wasn’t acquired from the environment (44). The
bacteria are secreted through the clitellum after exiting the bladder, the third loop
of the nephridia; these symbionts then enter the albumin of the egg capsule (43).
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A model for colonization of the earthworm embryo in the cocoon has also been
elucidated. The work of Davidson and her collaborators has shown that
colonization of the embryonic nephridia occurs when the nephridial canal
matures in a segment, this releases an attractant to draw in the V. eiseniae
bacteria (236). Another study looked into some V. eiseniae’s components
necessary for motility and colonization of embryonic nephridia. It was found that t
flagellar motility and type IV pili were necessary for proper colonization. The
twitching motility afforded by pilB and pilC is necessary for migration from the
albumin of the cocoon through the colonization pore and duct, the nephridiopore,
and the bladder. The flagellar motility conferred by flgK and flgL genes is
necessary for the final migration from the bladder to the ampulla where the
bacterium binds (237).
A further investigation of the nephridia and the symbiont has shown there
are additional bacteria involved in the process; these include novel
Microbacteriaceae and Flexibacteriaceae members and Hebraspirillum species.
The V. eiseniae bacterium, Microbacteriaceae, and Flexibacteriaceae bacteria
were present in both the cocoon and the adult nephridia; however, the
Hebraspirillum bacteria were at a lower than detectable level in the cocoon, and
may have been acquired from bedding or were in a lower than detectable level in
the cocoon. It was hypothesized that the presence of these bacteria other than
Hebraspirillium protects the earthworm embryos during development (43). This
was supported by an observation of suppressed growth of Herbaspirillum
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bacteria later in development, as it has a pathogenic role in the earthworm.
Another study has investigated Verminephrobacter species in multiple
earthworms. Nineteen of 23 lumbricid earthworms had one of these symbiont
species present. Sequencing of 16S rRNA and rpoB genes revealed that the
genetic similarity of symbionts corresponded to genetic similarity of the
earthworm host species, indicating coevolution (235). Despite ambiguity as to
the function of the symbiont, it is clear that it is beneficial for the bacterium, the
host, or both, as E. fetida and other related earthworms conserve the bacterium.

Earthworm Immunity
In order to evaluate the antimycobacterial activities of earthworms,
knowledge of their immune system is necessary. Invertebrates, including
earthworms, lack the antibody-based specific immunity of vertebrates (3).
Instead, they have an innate immunity with humoral responses mediated by
pattern recognition receptors and phagocytic responses including brown body
formation. These are associated with the coelomic fluid in the worm (4,45). In
addition to these, earthworms have skin consisting of an epidermis and a thin
cuticle containing mucopolysaccharides that act as an antimicrobial barrier
(238,239). The epidermis is composed of a layer of epithelial cells, basal cells,
and secretory cells. These basal cells help in the process of wound healing and
graft rejection, and often exert phagocytic activity (240,241).
The coelom is a cavity filled with coelomic fluid. This fluid contains cells
called coelomocytes; the transport of these cells and the fluid in the coelom is
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done using channels between segments of the worm. Each segment
possesses nephridia and a pore allowing draining of fluid into the environment
(12). Since this pore to the environment exists, the coelom is not aseptic and
always has bacteria, protozoans, and fungi, however the worm has ways to keep
these populations in check (242). One study reports that the coelomic fluid of
earthworms contains 6 x 105 bacteria/mL, with the number of suspected
phagocytic cells being ten times higher in concentration (243). The combination
of these phagocytic coelomic cells and humoral compounds keeps microbial
populations at tolerable levels (12).
The investigation into the compounds present in the coelomic fluid of
earthworms has led to the isolation of more than 40 proteins, that show cytolytic,
proteolytic, antimicrobial, hemolytic, hemagglutinating, tumorolytic, and mitogenic
activities (8-11). The majority of hemolytic proteins in Eisenia fetida species
show either bactericidal and/or bacteriostatic activity against numerous
pathogenic soil bacteria including Aeromonas hydrophila and Bacillus
megaterium, which are suspected earthworm pathogens (10,244-246). Some of
the proteins with antibacterial activity in the coelomic fluid are called Eisenia
fetida andrei factors or EFAFs, two specific glycoproteins secreted by
chloragocytes and eleocytes (244,247,248). These show antibacterial activity
against both Gram-positive and Gram-negative bacteria (10,249,250). These
have a particularly strong activity against bacteria pathogenic to the earthworm
(245,246,251). These EFAFs have now been characterized more specifically
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and named fetidins, one of these proteins with a corresponding DNA sequence
40 kDa length was cloned and found that its amino acid sequence has an Nglycosylation site and a peroxidase component (252,253). Another hemolytic
protein type with a length of 41 kDa that was identified independently was termed
a lysenin (254). Three discovered lysenin-related proteins were found to have
high sequence homology with fetidins (255). These proteins bind sphingomyelin
in the target cell membrane and create 3 nm pores (256,257). However, lysenin
acts on bacteria differently, since their membranes lack sphingomyelin (255).
Another of these substances is a bacteriolytic lysozyme, which breaks
down 1,4-β-D linkages between N-acetylmuramic acid and N-acetyl-Dglucosamine in peptidoglycan of bacterial cell walls. This helps to protect the
worm against bacterial infections, particularly those caused by Gram-positive
bacteria. Lysozyme effects are seen in extracts from both coelomocytes and
coelomic fluid extracts (258). Earthworm lysozyme has both lysozyme and
isopeptidase activities and is upregulated after a challenge with either Grampositive or Gram-negative bacteria (12).
Coelomic cytolytic factor (CCF) is a protein with known cytolytic activity
against invading bacteria; it is also a pattern recognition molecule (259). Patternrecognition molecules bind microbial pathogen-associated molecular patterns
(PAMPs). The PAMP recognized by CCF is the O-antigen of LPS of Gramnegative bacteria and muramyl dipeptide and muramic acid of peptidoglycan of
Gram-positive bacteria as well as β-1,3-glucanase and N,N’-diacetylchitobiose of
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yeast. (260-262). The mRNA for CCF is also upregulated upon microbial
stimulation (263). This molecule activates a prophenoloxidase cascade, causing
cytotoxic and antimicrobial compounds to form (264). CCF has two lectin-like
domains; one has homology with the polysaccharide and glucanase motifs of β1,3-glucanases and is located in the central part of the CCF. The C-terminal
tryptophan-rich domain interacts with N,N’-diacetylchitobiose, muramyl dipeptide,
and muramic acid (262). Despite homology with β-1,3-glucanases, this CCF
doesn’t show the same enzymatic ability (265-267). This compound is a
contributor to cell-mediated cytotoxic reactions and can be secreted by
phagocytic coelomocytes once stimulated by lipopolysaccharide (268). It has
also been demonstrated that CCF agglutinates Gram-positive and Gram-negative
bacteria (260). CCF and Tumor necrosis factor (TNF) also show some similarity.
However, anti-TNF antibodies don’t inhibit CCF indicating that different
mechanisms of action for lysis must exist between the two molecules (12).
Once bacteria have been disabled, they can be removed from the coelom
in several ways including: excretion through the nephridia, engulfment by cells in
the nephrostome or ampulla of the nephridia, phagocytosis by specific
coelomocytes and phagocytic cells (nonfunctional cells can then be excreted),
and encapsulation large foreign bodies including agglutinated bacteria or
parasites (11,269-271). In encapsulation, the process begins with recognition of
foreign material; this is then surrounded by coelomocytes, which form a capsule
also called a brown body around the material. When capsule then reaches a size
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of 1-2 mm wide, external cells lose adhesion with the epithelium such that the
capsule migrates toward the posterior segments to be eliminated (272-275). In
E. fetida, most typical brown bodies have wastes, agglutinated bacteria,
gregarines, or nematodes (11).
The coelomocytes present in the coelomic fluid are typically identified via
morphological and cytochemical differences (276,277). There are three main
types of coelomocytes: eleocytes and hyaline or granular amoebocytes.
Eleocytes or chloragogen cells have nutritive and accessory functions (278).
These include the collection of contaminants and other stray particulate in the
coelom and the also release some antimicrobial substances (12). Eleocytes also
have an identifiable collection of vesicles in their cytoplasm called chloragosomes
(279). Amoebocytes have immune functions including phagocytosis and cytokine
production (12). Granular amoebocytes tend to have increased phagocytic
activity over hyaline amoebocytes (276). The materials these phagocytes engulf
include inert particles, bacterial cell wall pieces, and foreign cells (269).
Phagocytosis by coelomocytes can be modified by humoral components as well
as opsonins, which coat the particle to enhance the process (280). In one
experiment, the phagocytic activity of coelomocytes was improved in the
presence of mammalian opsonins, IgG, and C3b (281). It has been observed
that the coelomic cells of Dendrobaena veneta show an increased phagocytosis
of known earthworm pathogens (Bacillus megaterium and Aeromonas
hydrophila) over non-pathogenic species, indicating specific recognition by the
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phagocytes (15). There is also evidence that EFAFs and CCF may have roles
in opsonization (259,282).

A Brief Restatement of Hypothesis and Methods
This study sought to determine whether or not the symbiotic bacteria of
Eisenia fetida have a role in immune-mediated defense against Mycobacterium
smegmatis. Thus, the hypothesis for this study is: the coelomic cells and fluid of
the earthworm E. fetida have antimycobacterial properties, which may be
influenced by the presence of V. eiseniae or other symbionts. In order to
examine the immune activity of the coelomic fluid of this worm against M.
smegmatis strain mc2155, the viability of mc2155 after treatment was studied.
Phagocytic interactions between coelomic cells and mc2155 bacteria were
observed with microscopy. The coelomic fluid and cells of both symbiont-positive
and symbiont-negative earthworms were assessed.
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3. Materials and Methods
Worm Populations
An earthworm colony (originally purchased from Carolina Biological) has been
maintained for several years at Minnesota State University, Mankato. For this
study, worms were routinely maintained on either a sphagnum moss or cellulose
bedding and fed a commercial worm food (Magic Worm Food, Magic Products,
WI). Bedding was replaced as needed and feeding occurred weekly.

Elimination of the Symbiont
Elimination of symbionts required sequential treatments with antibiotics. Control
worms (symbiont (+)) were treated in the same manner without antibiotics. For
each treatment 1:100 dilution of an antibiotic mix (10,000 units/mL of penicillin,
10 mg/mL of streptomycin, and 25 µg/mL of amphotericin B (Sigma; #A5995))
was prepared. A maximum of 11 worms were exposed in 10mL of antibiotics in 4
oz. glass jars per treatment period. The control worms were treated with
deionized water. Twenty-four seven-month-old Eisenia fetida earthworms were
cleaned to remove any bedding or slime on their body prior to placement in
antibiotics or water. These worms remained in jars with 20 mL of deionized
water, a 2 cm2 piece of paper towel and 3-5 mg of Magic Worm Food until the
next treatment. The antibiotic treatment was repeated 24, 48, and 72 hours after
the initial treatment. The antibiotic-treated and control worms were then placed
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in an 8 oz. plastic container along with moistened bedding. The container had
a perforated lid for airflow. These were kept at room temperature in the dark.

Development of a symbiont free colony
The treated worms were given food once a week and any cocoons produced by
the worms were counted and placed in jars. Any hatched worms were also
counted and placed in 8 oz. plastic containers. These worms were kept separate
by symbiont status and generation and were fed and checked for adult worms
weekly. Once adult worms were discovered they were placed in a larger 12 oz.
plastic container. This allowed for breeding of symbiont free populations. The
generation after the antibiotic treatment was used in the experiments as symbiont
(-) worms. All containers were kept in the dark at room temperature.

Confirmation of Symbiont Status
Cocoons from symbiont positive and negative worms were observed under a
dissecting microscope. Tested cocoons from each population had embryos that
hadn’t yet formed elongated worms and appeared to either have 4 eggs or be at
a 4-cell stage. The cocoons were washed and their contents were squeezed out
into a microfuge tube using forceps. The cocoon contents were suspended in 50
µL of 4% paraformaldehyde (50mM phosphate buffer, pH 7.4, 0.15M NaCl). The
tube was then incubated at room temperature for 2 hours. The microfuge tube
was centrifuged at 8 for 10 minutes (Mini-Centrifuge, Bel-Art Products, NJ), the
supernatant was poured off and the pellet resuspended in 1mL of phosphate
buffered saline (PBS); it was centrifuged at speed 8 for another 10 minutes. The
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supernatant was poured off and the PBS wash step was repeated. Then the
pellet was suspended in 50 µL of warmed hybridization buffer [(0.9 M NaCl, 0.02
M Tris-HCl pH 8, 30% formamide, 0.01% SDS) (Sigma-Aldrich; F9037), distilled
water, and 10% SDS with 10 µL of Verminephrobacter-specific probe, LSB 145
(S-G-Acidov-0145-a-A-18)] were added and the tube was incubated at 47°C for 2
hours. The tube was then centrifuged for 10 minutes at speed 8 and the
supernatant was removed. The pellet was suspended in 1mL of warmed wash
buffer (0.1 M NaCl, 0.02 M Tris-HCl, pH 8, 0.005M EDTA, distilled water, and
0.01% SDS) then incubated at 47°C for 20 minutes. The tube was then
centrifuged at speed 10 for 2 minutes to quickly pellet the cells, the supernatant
was poured off and the remaining pellet was suspended via pipetting. The
suspension was then pipetted on a slide, and a coverslip was sealed in place
with clear nail polish added along the edges. This slide was then observed using
a fluorescence microscope with TRITC and DAPI filters for the probe and the
worm tissue fluorescence, respectively. The symbiont fluoresced orange and the
symbiont-negative cocoon was confirmed as free of any fluorescence. The
symbiont positive cocoon was confirmed as having orange fluorescing bacteria.

Coelomic Cell Harvest
For each experiment four worms from control and treatment populations were
selected for coelomic cell harvest. These worms were cleaned in deionized
water and massaged to induce defecation. The worms were then transferred to a
sterile Petri dish containing 5mL of phosphate buffered saline (PBS). Each worm
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was then exposed to electric shock for 10 seconds using electrodes attached
to a 9-volt battery. The worms were then left in the dish for 10 minutes to allow
for coelomic fluid extrusion. The worms were then stripped of any mucus fluid,
containing cells, that covers their body and they were returned to their bedding to
recover for future procedures. The PBS and mucus fluid was then transferred to
a sterile tube. Five milliliters of PBS were then added to the plate to collect any
additional mucus fluid remaining and added to the tube. This tube was then
centrifuged for 10 minutes at 1000 rpm (200 x g). The supernatant fluid was
passed through a 0.45µm filter into a sterile tube; this was used for the filtered
extract treatment. The pellet was resuspended with 2.5mL of PBS and 20µL of
the fluid were added to a hemacytometer. This suspension was examined under
the microscope and all coelomic cells were counted in five 0.1 mm3 grids. The
number of cells per 0.1 mm3 was used to calculate coelomic cell concentration.
The remaining suspension was used for coelomic cell association trial.

mc2155 Maintenance and Dilution
A frozen stock culture of Mycobacterium smegmatis strain mc2155 provided by
Dr. Timothy Secott was used to inoculate 9mL of tryptic soy broth (TSB)(BBL).
This culture was grown at 37°C for 3 days and was used as the source of weekly
cultures used for the experiment. Several days prior to an experimental trial, a
loopful of the TSB culture was added to 9 mL TSB containing 5 µL of Tween 80
and incubated for 3 days at 37°C. The culture was measured for turbidity using a
Spec 20 spectrophotometer (Bausch and Lomb) set at 600nm. The culture was
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-4

-5

then diluted using 1% peptone blanks to optical densities of 1x10 , 5x10 ,
2.5x10-5, and 1.25x10-5.

Coelomic Fluid Extract Treatment of mc2155
In microfuge tubes, 200 µL of PBS were added to either 200µL of the symbiont
positive or negative extracts for extract controls. Also, 200µL of the different M.
smegmatis dilutions and 200 µL of PBS were added to tubes for mycobacterial
controls. Aliquots of 200µL of symbiont-positive or -negative extracts were added
to the M. smegmatis dilutions for the experimental trials. After a 30-minute
incubation at room temperature, 100µL of each solution was spread-plated on of
tryptic soy agar (TSA). These plates were then incubated at 37°C for 3 days.
The plates were then counted for M. smegmatis colonies and any colony merging
or contaminants were noted.

Coelomic Cell Association Treatment
Using a concentration of mc2155 determined by spectrophotometer (between
0.140 and 0.980 across the trials), the culture was diluted in three 1:10 dilutions
in 1% peptone. A volume of 200µL of each dilution and the undiluted bacteria
was mixed separately with 200µL of coelomic cells harvested from symbiont (+)
and symbiont (-) worms. The coelomic cells alone and the mycobacteria alone
were added to 200µL of PBS as control treatments. These tubes were then
allowed to incubate at room temperature for 30 minutes. After incubation, the
tubes were centrifuged at speed 5 for 10 minutes (Bel-Art Mini centrifuge) and
the supernatant was poured out. The pellet was then suspended using the
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remaining liquid and approximately 100µL were smeared onto each slide and
allowed to dry. The smears were then Gram stained. These slides were then
observed at 1000x magnification and 300 total coelomic cells were counted as
either adhered with or not adhered with mycobacteria. If any slides had too high
of a mycobacterial concentration causing nearly all coelomic cells to appear as
having adherent mycobacteria they were not used for the count or the study.
This was also true if a slide had less than 300 coelomic cells. The coelomic cells
without mycobacteria were used as a control to ensure there were no
contaminant bacteria giving false positives for the experimental bacteria.

Statistical Analysis
To determine differences between the symbiont (+) and (-) populations as well as
between the untreated mycobacteria, statistical analyses were performed in
SPSS. For the coelomic association trials, a univariate analysis was performed
to determine differences in percent association at the different dilutions.
Individual differences were determined by a Tukey HSD or by Games Howell in
the case of nonhomogeneous variances determined by a Levene’s Test.
Univariate analyses were also performed on the variables associated with the
cell-free coelomic extract treatments of mc2155. These were also tested for
homogeneity of variances with the Levene’s test and individual significant
differences assessed by the Tukey HSD test or Games-Howell test for
nonhomogeneous data. To determine differences among the survival
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percentages for symbiont (+), symbiont (-), and mycobacterium alone
populations, univariate analysis was performed.
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4. Results
The antimycobacterial activity of soluble compounds and coelomic cells in
the coelomic fluid of symbiont (+) and (-) E. fetida earthworms were assessed in
this project.

Adherence
The number of cells with mycobacteria adhered to their surface was
divided by the total cells (300) counted to obtain the percent association; three
concentrations of mc2155 bacteria were used. As the concentration decreased,
so did adherence (Fig. 1). Differences exist between the percent associations
corresponding to the varying dilutions when p=0.01 was used as the level for
significance, but not by symbiont status (+) or (-) at each dilution (p= 0.663). All
individual probabilities are displayed in Appendix A.

Percent Adherence (%)

80
70
60
50
40

Symbiont (+)

30

Symbiont (-)

20
10
0

1.0x10-3

1.0x10-2

1x10-1

Dilution of Bacterial Culture

Figure 1-Percent Association by Dilution-Significant differences exist between
the different dilutions, but not by symbiont status.
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Antimycobacterial Activity
To determine if the coelomic fluid had antimycobacterial activity, the fluid
was mixed with different concentrations of mc2155 cells, incubated, and aliquots
of the mixes spread-plated for viable bacterial counts. Using a 72-hour culture,
dilutions with PBS were made to 1x10-4, 5x10-5, 2.5x10-5, and 1.25x10-5 OD. Two
dilutions were used per trial.
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Table 1-The Effect of Coelomic Fluid Treatment on Mycobacterium
smegmatis mc2155 Concentration Viability
Trial Number

1

2

3

4

5

6

7

Concentration Symbiont (+)
of mc2155
Average
(OD600)
CFU/mL
mc2155

Symbiont (-)
Average
CFU/mL
mc2155

Mycobacterium
Alone
Average
CFU/mL mc2155

1.00x10-4

TMTC

TMTC

1.90x107

5.00x10-5

2.60x107

4.14x107

4.46x107

1.00x10-4

1.73x107

1.34x107

1.17x107

5.00x10-5

2.14x107

2.24x107

2.08x107

1.00x10-4

8.50x106

1.05x107

1.42x107

5.00x10-5

2.10x107

2.40x107

1.88x107

1.00x10-4

1.46x107

1.93x107

TMTC

5.00x10-5

2.76x107

3.02x107

2.86x107

5.00x10-5

3.48x107

3.18x107

2.98x107

2.50x10-5

8.16x107

6.08x107

4.69x107

2.50x10-5

2.60x107

3.80x107

1.52 x107

1.25x10-5

3.92x107

3.84x107

7.28 x107

2.50x10-5

3.60x107

3.28x107

TMTC

1.25x10-5

4.16x107

3.12x107

TMTC

No treatment type was significantly different than the others. TMTC: Too Many
Colonies to Count (> 300).
Overall, when mc2155 bacteria were treated with the fluid, no difference in
surviving bacteria occurred by source of the coelomic fluid (symbiont (+) or (-))
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nor did the coelomic fluid-treated bacterial concentrations differ from the
untreated mycobacteria (Table 1).
ANOVA of the different trials indicated a significant difference (p= 0.001)
among the trials of surviving bacteria. Post hoc tests indicated differences
between trials 2 and 5 (p= 0.004), 2 and 6 (p= 0.033), 3 and 5 (p= 0.002), and 3
and 6 (p= 0.019). These correspond to differences due to the concentration of
bacteria added.

mc2155 Concentration (CFU/mL)

4.5E+07
4.0E+07
3.5E+07
3.0E+07

Mycobacterium Alone

2.5E+07

Symbiont (+)

2.0E+07

Symbiont (-)

1.5E+07
1.0E+07
5.0E+06
0.0E+00
5.00x10-5

1.00x10-4

Absorbance of mc2155 (OD600)

Figure 2a- The Effect of Coelomic Extract Treatment on Higher
Concentrations of Mycobacterium smegmatis mc2155- The diluted
concentration of mc2155 in trials 1-4 are compared amongst the different
treatments for the lower concentration dilutions. Trial 5 was excluded from the
figure due to results falling between the high and low concentration groups.
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8.0E+07

mc2155 Concentra.on (CFU/mL)

7.0E+07
6.0E+07
5.0E+07

Mycobacterium Alone

4.0E+07

Symbiont (+)
Symbiont (-)

3.0E+07
2.0E+07
1.0E+07
0.0E+00
1.25x10-5

2.50x10-5

Absorbance of mc2155 (OD600)

Figure 2b- The Effect of Coelomic Extract Treatment on Lower
Concentration Mycobacterium smegmatis mc2155-The diluted concentration
of mc2155 in trials 6 and 7 is compared amongst the different treatments for the
lower concentration dilutions. As bacterial concentration in OD increased, viable
concentration decreased.

ANOVA revealed a significant difference between the surviving
mycobacteria by the different dilutions (p <0.001). This difference was found
using the Welch test, as there was a lack of homogeneity of variance (p= 0.006).
The individual differences were found via a Games-Howell test also due to the
lack of homogeneity of variance. The only significant difference was between the
1x10-4 and 5x10-5 dilutions (p<0.0001).
Mycobacterium smegmatis mc2155 produced a higher bacterial
concentration at lower absorbance dilutions than at lower concentration dilutions
(Table 1, Figs. 2a & 2b). However, despite significant increases in initial
concentration, no significant differences existed between the two coelomic fluid
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treated bacteria. The only significant differences found were between some of
the different initial concentrations within each coelomic fluid treatment
(Appendices B-D) and some at the differences between the coelomic fluid
treatments (Appendices E-G).
Table 2-Average Pooled Percent Survival by Treatment- Differences in
percent survival occurred by dilution but not by treatment (symbiont (+) or (-)).
Symbiont (+) Coelomic
Symbiont (-) Coelomic
Initial Concentration of
Fluid Mean Percent
Fluid Mean Percent
mc2155 (OD600)
Survival ± SD
Survival ± SD
1x10-4

89.98 ± 30.12

96.21± 29.96

5x10-5

91.72 ± 19.68

105.05 ± 26.41

2.5x10-5

186.01± 115.18

170.47± 57.87

1.25x10-5*

55.49 ± 2.33

47.80 ± 6.99

*-Only one set of untreated controls yielded countable plates
The percent survival statistic was calculated using the average
concentration of untreated mycobacteria as 100%. The bacterial concentration
from each dilution was used to calculate the percentage (Table 2). Significant
differences occurred by dilution (p=0.004) but not by population (p=0.963). No
interaction was observed between dilutions and treatment populations
(p=0.940). All individual differences are noted in Appendices H-J.
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mc2155 Concentration (CFU/mL)

9.0E+07
8.0E+07
7.0E+07
6.0E+07
5.0E+07

Mycobacterium Alone

4.0E+07

Symbiont (+)

3.0E+07

Symbiont (-)

2.0E+07
1.0E+07
0.0E+00
0

100 200 300 400 500 600 700 800 900
Coelomic Cell Concentration (Cells/mL) x 103

Figure 3-Mycobacterium smegmatis mc2155 Concentration After Treatment
with Coelomic Cell Extract by Coelomic Cell Concentration and Treatment
Group- The symbiont (+) and (-) treatments seem to stratify with a bit of overlap
with the symbiont (-) garnering more coelomic cells. However, there is no
significant difference between the coelomic cell concentrations or treatment
types.
Coelomic cell concentration varied from trial to trial, however coelomic cell
concentration didn’t correspond to an increase or decrease in mc2155
concentration by cluster (Fig. 3). A correlation of 0.165 existed (r2=0.027)
between coelomic cell concentration and surviving mycobacteria, but this was not
found to be significant (p= 0.421).
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mc2155 Concentration (CFU/mL)

Variability in Bacterial Cultures and Coelomic Cell
Concentration
80000000

y = 3E+07e-0.086x
R² = 0.00067

70000000
60000000
50000000
40000000
30000000
20000000
10000000
0.00

0.10

0.20

0.30
mc2155

0.40
0.50
0.60
Absorbance (OD600)

0.70

0.80

Figure 4- Mycobacterium smegmatis mc2155 Concentration by Absorbance
of Starting Culture-There were increasing plate counts with increasing
absorbance, dropping off at 0.696. No significant differences were detected
overall.
Quantified bacterial concentrations exhibited great variability in the 72hour cultures of mc2155 used in these experiments. Generally speaking as the
absorbance of the culture increased there was a resulting increase in plate count.
However, an examination of the starting culture absorbance values (Fig. 4)
revealed no significant difference between plate counts (p= 0.066) at the different
measured absorbance values for a 72-hour culture. Due to a lack of
homogeneity of variances, a Welch test and a Games-Howell post-hoc test was
also performed. This did reveal a difference (p= 0.037) in bacterial concentration
between the starting absorbance values of 0.165 and 0.484.
The viable counts increased when the bacteria were diluted (Fig. 5). No
significant differences in concentrations were found between the different
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dilutions (p=0.055). This was found using a Kruskal-Wallis test, which was
necessary due to a lack of normality of the 1.25 x 10-5 dilution.

mc2155 Concentration (CFU/mL)

8.0E+07
7.0E+07
6.0E+07
5.0E+07
4.0E+07
3.0E+07
2.0E+07
1.0E+07
0.0E+00
1.25x10-5

2.50x10-5

5.0x10-5

1.0x10-4

Absorbance of mc2155 (OD600)

Figure 5-Average Colony Counts of Untreated Mycobacterium smegmatis
mc2155 by Dilution-As the absorbance increased bacterial concentration
decreased, however no significant differences were found. Only one sample of
the 1.25x10-5 dilution was viable so no standard deviation was calculated.
An examination of the mycobacterial concentration in relation to coelomic
cell concentration revealed a clustering of coelomic cell concentration by
population (Fig. 3). A comparison of the coelomic cell concentrations (Figures 3
& 6) between the symbiont (+) and (-) shows a significant difference (p= 0.001).
This difference shows an increased mean coelomic cell concentration in the
symbiont (-) population of 4.46 x 105 coelomic cells/mL over the symbiont (+)
population of 2.70 x 105 coelomic cells/mL.

Coelomic Cell Concentration (Cells/mL)
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8.0E+05
7.0E+05
6.0E+05
5.0E+05
4.0E+05

Symbiont (+)

3.0E+05

Symbiont (-)

2.0E+05
1.0E+05
0.0E+00
1

2

3

4

5

6

7

Trial Number

Figure 6- Variable Coelomic Cell Concentration by Trial and Worm
Population-Coelomic cell counts are the compilation from four earthworms’
ceolomic exudates.
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5. Discussion
Adherence of Coelomic Cells with Mycobacteria
This project sought to elucidate any possible antimycobacterial activity
present in the earthworm Eisenia fetida and whether a previous disruption of
normal microbiota would affect this activity. The first system used coelomic cells
extracted from symbiont (+) and (-) earthworms and three dilutions of
Mycobacterium smegmatis mc2155 bacteria. It was found that the percentage of
coelomic cells with associated mycobacteria was not significantly different in the
worm populations after disruption of the earthworm microflora. This indicates
that the nephridial symbionts had no effect on the coelomic cell binding of
mc2155 cells.
Furthermore, as the bacterial concentration in the mixtures decreased, the
percentage of coelomic cells with adhered bacteria also decreased, however this
decrease in percentage adhered was not proportional to the 10-fold decrease in
concentration. The high association observed may have been due to the higher
number of bacteria remaining after the wash step. The remaining unbound
bacteria may have associated with coelomic cells once they were placed on
slides. The lower two concentrations of bacteria used differed in percent
adherence by 50%. Thus, it appears as though either a low proportion of
coelomic cells can bind M. smegmatis or the binding requires an increased
incubation time or different conditions for adherence. If phagocytes specifically

57
recognized mycobacteria, similar binding proportions would be seen across at
least two of the dilutions. The higher concentrations of bacteria were not useful
for determining coelomic cell association, due to the sheer numbers of bacteria
on the slide.
There may be other considerations to take into effect with the
experimental design including the use of PBS in the experiment. There was
passive adherence of the bacteria to the coelomic cells in this solution, but
without an energy source the coelomic cells may be unable to bind tightly to the
bacteria. It is possible that a longer incubation time may be necessary for proper
recognition and adherence of the mycobacteria and a nutrient source may be
necessary for that longer incubation. However, an incubation time longer than 34 hours may allow M. smegmatis to replicate, affecting bacterial concentration in
solution (173). Thus, the bacteria may have to be inactivated or a slower growing
species like MAP may have to be used.

Assessment of Coelomic Fluid for Antimycobacterial Activity
The assessment of antimycobacterial activity by reductions in viable plate
counts was plagued with issues related to inconsistent growth by the bacteria.
However, cell-free coelomic-cell extracts from symbiont (+) and (-) worms
resulted in no significant difference in the concentrations of surviving bacteria.
Two compounding problems arose with this method. There is a certain amount
of variation in coelomic cell concentrations from trial to trial, as well as differences
in bacterial plate counts. If there was variability related to the coelomic cell
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concentration prior to filtration of the fluid, it was not significant. Also even
though the coelomic cell concentration varied from trial to trial, no resulting
significant difference in plate count was observed.
Compared to common model bacteria such as E. coli that are easier to
manipulate, Mycobacterium smegmatis culture presents difficulties. Firstly, this
bacterium grows slower than some common model bacteria, taking 2-3 days to
grow colonies or a turbid culture. However, M. smegmatis is preferable to other
strains of mycobacteria that take weeks to months to grow. Also, this bacterium
grows in clumps; in broth culture it tends to form a flaky mat on the surface of the
liquid and on agar plates the bacteria form spreading colonies. To aid dispersal
of bacteria, the surfactant Tween 80 was added to the culture medium. However,
inconsistencies in the dilutions still occurred. However, more dilute starting
concentrations yielded more countable plates. A related issue is also the
fluctuations in the absorbance of the starting cultures for each trial. The mid-log
phase for M. smegmatis (at 600nm) is 0.5 OD and most of the cultures fell near
that absorbance (283). However, if the bacteria aren’t fully in solution, the OD
may be inaccurate and the dilution may be too high or low as a result.
Despite the variability of bacterial cultures, no evidence of
mycobactericidal activity in the cell free coelomic fluid was found. Since the
concentration of coelomic cells used to make the extracts also varied with each
trial, they added to possible inconsistency in results. While coelomic cell
concentration differed by trial overall, the symbiont (-) population yielded a
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significantly higher coelomic cell concentration than the symbiont (+)
population. How these differences in coelomic yield relate to the loss of bacterial
symbionts remains unclear. Coelomic cells function in the innate immune
defenses of the earthworm (12). It may be a compensatory increase in immune
cells to act on bacteria that have taken up residence in areas normally occupied
by symbiotic bacterial flora. Thus, the increase in coelomic cell production may
be a result of a persistent inflammatory reaction in response to disrupted
bacterial populations in the worm. Conversely, the increase in coelomic cell
concentration may indicate the microflora of the worm may be essential to the
regulation of innate response. Another possibility is that the symbiont’s presence
during development helps to acclimatize the cells’ immune response.
This project has assessed the coelomic fluid and coelomic cells of E.
fetida earthworms for antimycobacterial activity. By the parameters of this
project, there has been no obvious activity against M. smegmatis. An
assessment of Lumbricus terrestris earthworms in MAP-infested soil suggested
resistance to mycobacteria, as few worms in that environment had detectable
MAP in their gut (40). If that kind of antimycobacterial activity also exists in E.
fetida, it likely isn’t occurring via phagocytic recognition or antimycobacterial
substances in the coelomic fluid. MAP may be recognized differently by L.
terrestris than M. smegmatis by E. fetida. A survey of tissue samples and
coelomic cells of the both earthworm guts for mycobacteria in both of these
instances might be useful to elucidate the method of elimination.
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The null hypothesis that E. fetida coelomic cells and fluid exhibit no
antimycobacterial properties was upheld in this instance. Disruption of symbiotic
bacteria in this earthworm had no direct effect on phagocytic activity of the
coelomic cells or bactericidal/bacteriostatic properties of the coelomic fluid.
Under the conditions of these experiments, treatment of mycobacteria with
coelomic fluid showed no apparent negative effect on mycobacterial growth
compared to the untreated mycobacteria after treatment, as there was no
significant reduction in viability in either of the treated populations. The data
demonstrated that no antimycobacterial activity against M. smegmatis could be
observed.
There are some variations on methodology that one could explore in future
research. This research only used 4 worms for coelomic cell harvest; higher
concentrations of coelomic cells may have yielded detectible activity. This would
necessitate additional worms per harvest. If additional worms were used, a more
concentrated fluid of any antimicrobial substances could possibly show more
obvious results and gradations down to a minimum inhibitory/bactericidal
concentration could be found.
Another area to investigate would be the potential injury suffered by the
mycobacteria after coelomic fluid treatment. The bacteria may be damaged in
some way that is not readily apparent by plate count. If working with more
concentrated coelomic fluid than used in this study in combination with
visualization, perhaps by using electron microscopy, one might be able to see

61
changes in the cell wall structure or atypical cell shape as a result of treatment.
This was a method used previously to observe the damage of another earthworm
derived antimycobacterial substance (7). Alternatively, injury may make the
bacteria more susceptible to a second assault that could result in death. This
research used only M. smegmatis. Since there has been noted antimicrobial
activity in coelomic fluid previously, it is possible that these worms may have
activity against another bacterium of interest such as certain troublesome Gram
(-) bacteria (4,249,250,284). Another possibility is that an injury might progress
to a fatal injury after a longer incubation period was used prior to plating.
The most intriguing data from this project are the coelomic cell
concentration differences between symbiont (+) and (-) earthworms. A larger
survey of these earthworm populations, either with more worms per harvest or
more harvests overall, would be beneficial to see if this is a consistent trend in
regards to symbiont status or if this was only in relation to the two separate
breeding populations used in this study. Since the aim of the study didn’t directly
address coelomic cell concentrations, the data are unfortunately limited in this
area. However, resident microflora do exert an antimycobacterial influence in
another earthworm species (7). Thus, disruption of the microbiota of the worms
used in the study may exhibit different susceptibilities to earthworm pathogens.
The increased concentration of coelomic cells in the disrupted worms
indicates that there is a need for more immune cells than in untreated worms.
The loss of Verminephrobacter eiseniae cannot be determined as the cause of
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the increase in coelomic cells, as other bacteria were likely eliminated from the
worms when they were treated with antibiotics. Only V. eiseniae was assayed as
it is a well-described symbiont of the worm and the loss of this symbiont indicated
a disrupted microbiota.
This experiment focused on the phagocytic coelomocytes or amoebocytes
but also indirectly investigated the production of antimicrobial substances by
eleocytes (12). It appears as though no phagocytic recognition occurred, based
on the data collected in this experiment. However, it is possible that an
antimycobacterial substance produced by eleocytes in the coelomic fluid may
have been present, but at too low a level to show a noticeable effect on mc2155
plate counts.

Conclusion
In closing, this project investigated the effects of disrupting the bacterial
flora and symbionts from E. fetida on potential antimycobacterial defenses. No
significant trends with regard to phagocytic activity or direct antimycobacterial
activity were observed. While some aspects of this study could be modified to
further examine these trends possibly using more concentrated extracts, this
would appear to be an unproductive area to pursue. The most likely area of
interest would be the effect of symbiont removal on the coelomic cell populations.
A closer examination of the earthworm’s physiological response to the antibiotic
treatment may elucidate the source of the coelomic cell concentration
discrepancy.
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Appendices
Appendix A-Probability Values of Average Mycobacterial Concentration
Between All Dilutions for Both Symbiont (+) and (-) Treated Mycobacteria
Dilution
and
Treatment

1x10-3
Symbiont
(+)
1x10-3
Symbiont
(-)
1x10-2
Symbiont
(+)
1x10-2
Symbiont
(-)
1x10-1
Symbiont
(+)
1x10-1
Symbiont
(-)

p-value
against
1x10-3
Symbiont
(+)

p-value
against
1x10-3
Symbiont
(-)

p-value
against
1x10-2
Symbiont
(+)

p-value
against
1x10-2
Symbiont
(-)

p-value
against
1x10-1
Symbiont
(+)

p-value
against
1x10-1
Symbiont
(-)

-----

0.793

0.032

0.001

<0.0001

<0.0001

0.793

-----

0.012

0.002

<0.0001

<0.0001

0.032

0.012

-----

0.534

0.003

<0.0001

0.001

0.002

0.534

-----

.535

<0.0001

<0.0001

<0.0001

0.003

.535

-----

0.636

<0.0001

<0.0001

<0.0001

<0.0001

0.636

-----

Tukey HSD testing was used to determine p-values; in cases of inequality of
variances the Games-Howell test was used.
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Appendix B-Probability Values of Untreated Mycobacteria Average
Mycobacterial Concentration Between Different Dilutions
1.00x10-4
5.00x10-5
2.50x10-5
1.25x10-5
Dilution and
Mycobacteriu Mycobacteriu Mycobacteriu Mycobacteriu
Treatment
m Alone
m Alone
m Alone
m Alone
-4
1.00x10
Mycobacteriu
--0.390
0.648
0.001
m Alone
5.00x10-5
Mycobacteriu
0.390
--0.985
0.005
m Alone
2.50x10-5
Mycobacteriu
0.648
0.985
--0.005
m Alone
1.25x10-5
Mycobacteriu
0.001
0.005
0.005
--m Alone
All p-values were found by Tukey HSD testing.
Appendix C-Probability Values of Symbiont (+) Coelomic Fluid Treated
Average Mycobacterial Concentration Between Different Dilutions
Dilution and
1x10-4
5x10-5
2.5x10-5
1.25x10-5
Treatment
Symbiont (+)
Symbiont (+)
Symbiont (+)
Symbiont (+)
-4
1.00x10
--0.057
0.403
0.011
Symbiont (+)
5.00x10-5
0.057
--0.657
0.014
Symbiont (+)
2.50x10-5
0.403
0.657
--0.967
Symbiont (+)
1.25x10-5
0.011
0.014
0.967
--Symbiont (+)
Differences were found by Games-Howell (lack of heterogeneity of variances
p=0.005)
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Appendix D- Probability Values of Symbiont (-) Coelomic Fluid Treated
Average Mycobacterial Concentration Between Different Dilutions
Dilution and
1.00x10-4
5.00x10-5
2.50x10-5
1.25x10-5
Treatment
Symbiont (-)
Symbiont (-)
Symbiont (-)
Symbiont (-)
-4
1.00x10
--0.156
0.014
0.132
Symbiont (-)
5.00x10-5
0.156
--0.223
0.917
Symbiont (-)
2.50x10-5
0.014
0.223
--0.700
Symbiont (-)
1.25x10-5
0.132
0.917
0.700
--Symbiont (-)
All p-values were found by Tukey HSD testing.
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Appendix E-Probability Values of Untreated Mycobacteria Against
Coelomic Fluid Treated Average Mycobacterial Concentration Between
Different Dilutions
1.00x10-4
5.00x10-5
2.50x10-5
Dilution and
Mycobacterium
Mycobacterium
Mycobacterium
Treatment
Alone
Alone
Alone
1.00x10-4
Symbiont (+)

0.680

0.049

0.365

5.00x10-5
Symbiont (+)

0.011

0.478

0.885

2.50x10-5
Symbiont (+)

0.025

0.688

0.677

1.25x10-5
Symbiont (+)

0.002

0.080

0.298

1.00x10-4
Symbiont (-)

0.874

0.060

0.355

5.00x10-5
Symbiont (-)

0.035

0.847

0.698

2.50x10-5
Symbiont (-)

0.002

0.353

0.419

1.25x10-5
Symbiont (-)

0.002

0.495

0.560

The untreated mycobacteria didn’t have countable plates at the 1.25x10-5 dilution
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Appendix F- Probability Values of Symbiont (+) Coelomic Fluid Treated
Average Mycobacterial Concentration Against Symbiont (-) Coelomic Fluid
Treated and Untreated Average Mycobacterial Concentration at Between
Different Dilutions
Dilution and
1.00x10-4
5.00x10-5
2.50x10-5
1.25x10-5
Treatment
Symbiont (+)
Symbiont (+)
Symbiont (+)
Symbiont (+)
-4
1.00x10
Mycobacterium
0.680
0.011
0.025
0.002
Alone
5.00x10-5
Mycobacterium
0.049
0.478
0.688
0.080
Alone
2.50x10-5
Mycobacterium
0.365
0.885
0.677
0.298
Alone
1.00x10-4
0.812
0.013
0.026
0.004
Symbiont (-)
5.00x10-5
0.026
0.252
0.252
0.046
Symbiont (-)
2.50x10-5
0.003
0.800
0.800
0.136
Symbiont (-)
1.25x10-5
0.039
0.046
0.046
0.346
Symbiont (-)
The untreated mycobacteria didn’t have countable plates at the 1.25x10-5 dilution
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Appendix G-Probability Values of Symbiont (-) Coelomic Fluid Treated
Average Mycobacterial Concentration Against Symbiont (+) Coelomic Fluid
Treated and Untreated Average Mycobacterial Concentration Between
Different Dilutions
Dilution and
1.00x10-4
5.00x10-5
2.50x10-5
1.25x10-5
Treatment
Symbiont (-)
Symbiont (-)
Symbiont (-)
Symbiont (-)
-4
1.00x10
Mycobacterium
0.874
0.035
0.002
0.002
Alone
5.00x10-5
Mycobacterium
0.060
0.847
0.353
0.495
Alone
2.50x10-5
Mycobacterium
0.355
0.698
0.419
0.560
Alone
1.00x10-4
0.812
0.026
0.003
0.039
Symbiont (+)
5.00x10-5
0.013
0.252
0.004
0.150
Symbiont (+)
2.50x10-5
0.026
0.800
0.409
0.538
Symbiont (+)
1.25x10-5
0.004
0.046
0.136
0.346
Symbiont (+)
The untreated mycobacteria didn’t have countable plates at the 1.25x10-5 dilution
Appendix H-Probability Values of Mean Percent Survival of Symbiont (+)
Treated Mycobacteria Between Different Dilutions
Dilution and
1x10-4
5x10-5
2.5x10-5
1.25x10-5
Treatment
Symbiont (+)
Symbiont (+)
Symbiont (+)
Symbiont (+)
-4
1.00x10
--1.000
0.593
0.411
Symbiont (+)
5.00x10-5
1.000
--0.596
0.046
Symbiont (+)
2.50x10-5
0.593
0.596
--0.416
Symbiont (+)
1.25x10-5
0.411
0.046
0.416
--Symbiont (+)
Differences were found by Games-Howell (lack of heterogeneity of variances
p=0.005)
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Appendix I-Probability Values of Mean Percent Survival of Symbiont (-)
Treated Mycobacteria Between Different Dilutions
Dilution and
1.00x10-4
5.00x10-5
2.50x10-5
1.25x10-5
Treatment
Symbiont (-)
Symbiont (-)
Symbiont (-)
Symbiont (-)
1.00x10-4
--0.985
0.115
0.479
Symbiont (-)
5.00x10-5
0.985
--0.122
0.282
Symbiont (-)
2.50x10-5
0.115
0.122
--0.019
Symbiont (-)
1.25x10-5
0.479
0.282
0.019
--Symbiont (-)
All p-values were found by Tukey HSD testing.

Appendix J- Probability Values of Mean Percent Survival of Symbiont (+)
and (-) Treated Mycobacteria Between Different Dilutions
Dilution and
1.00x10-4
5.00x10-5
2.50x10-5
1.25x10-5
Treatment
Symbiont (-)
Symbiont (-)
Symbiont (-)
Symbiont (-)
-4
1.00x10
0.812
0.514
0.122
0.128
Symbiont (+)
5.00x10-5
0.832
0.394
0.135
0.008
Symbiont (+)
2.50x10-5
0.308
0.347
0.851
0.173
Symbiont (+)
1.25x10-5
0.142
0.013
0.075
0.346
Symbiont (+)
All p-values were found using a t-test accounting for lack of homogeneity of
variances (Levene’s Test for Symbiont (+) p=0.005)

